Drugs / TBI-1301
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02869217 | Sep 2016 → Nov 2026 expected | esophageal cancer, liver cancer, lung cancer, melanoma +3 | University Health Network, Toronto | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02366546 | Mar 2015 → Sep 2018 | cancer | Mie University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03250325 | Sep 2017 → Jan 2020 | synovial sarcoma | Takara Bio Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07174427 | Jan 2026 → Mar 2032 expected | synovial sarcoma | Takara Bio Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBI-1301 | “Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.” NCT07174427 ↗ |
| Action | Deplete | “TCR-T cells exhibited cytotoxic effects against NY-ESO-1-expressing tumor cells” PMID 35768164 ↗ Jun 2022 |
| Modality | Cell therapy | “the TCR-transduced T-cell product (TBI-1301)” PMID 35768164 ↗ Jun 2022 |
| Route | Intravenous | “given back to the subject through an intravenous infusion” NCT02869217 ↗ |